New oral drug combo shows promise in early cancer trial
NCT ID NCT01534598
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose for future studies, not to prove effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FdCyd (5-fluoro-2'-deoxycytidine) and THU (tetrahydrouridine)
- What this could lead to
- If this works, it could point toward a new oral treatment option for advanced solid tumors that have not responded to standard therapies.
- What could go wrong
- This is a very early Phase I trial with only 59 participants, focused on safety and dosing. It is not yet proven to work, and side effects are unknown. Many early-stage cancer drugs do not advance to become treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
Duarte, California, 91010, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Penn State
Hershey, Pennsylvania, 17033, United States
-
UC Davis Cancer Center
Sacramento, California, 95817, United States
-
USC Norris Cancer Center
Los Angeles, California, 90033, United States
-
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a simple text message transform cancer care?
- Can modern Radiotherapy's late effects be predicted?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva